Transfusion Medicine Articles & Analysis
10 news found
Last year, during Black History Month, our team at MedSource Labs took a closer look at the world of medical illustration and the ongoing efforts to address the lack of diversity in the field. We were inspired by the work of medical illustrators who are breaking barriers and ensuring that healthcare visuals represent the full spectrum of patients they serve. To see video, please click here What ...
We are excited to invite you to the 38th International ISBT Congress in Barcelona, Spain, from June 23-27. This highly anticipated transfusion medicine congress will bring together experts and professionals from all over the world to share their latest research, ideas, and experiences in the field. Come join us and be part of this exciting opportunity to learn ...
While IVS currently focuses on applications of the LITATM in cardiac safety and discovery projects, IVS has plans for developing a wide range of useful applications in treatment development for regenerative medicine, cancer, autoimmune disorders, and a wide range of rare diseases. ...
Second, the opportunity to extend Quidel’s point-of-care testing to include clinical laboratories and transfusion medicine once we successfully close our acquisition of Ortho. ...
It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. ...
” Karoly Nikolich, CEO of Alkahest, said, “We are excited to join forces with Grifols, an industry leader in plasma-derived medicines, to realize our shared vision and mission of delivering innovative medicines for age-related diseases on an ambitious ...
The net debt leverage ratio continues improving to 4.12x Grifols leads the development of an anti-SARS-CoV-2 immunoglobulin, a treatment using plasma from recovered COVID-19 patients, and a highly sensitive diagnostic test Grifols closes its strategic alliance deal with Shanghai RAAS to boost sales of plasma-derived medicines and transfusion diagnostic ...
Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS) Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales ...
The Diagnostic Division’s sales grew by 4.5% (1.1% cc) to EUR 734 million. Revenues generated from transfusion medicine solutions continue to drive the division´s performance with a positive upward trend in NAT donor-screening solutions, used to detect viruses in blood and plasma donations, blood typing and recombinant proteins. ...
Grifols and the Public Investment Fund of Saudi Arabia (PIF) have executed a non-binding term sheet to build a network of plasma collection centers and other facilities for the production of plasma medicines, including a plasma fractionation plant and a purification plant, in Saudi Arabia. ...